News
CYYNF
0.150
NaN%
--
Cynata Extends R&D Tax Incentive Loan Ahead of $1.7m Rebate
TipRanks · 1d ago
Cynata Updates Corporate Governance Framework to Strengthen Board Oversight
TipRanks · 3d ago
Cynata Releases 2025/2026 Annual Report and Confirms Corporate Structure
TipRanks · 3d ago
Cynata Adjusts 2026 Results After GvHD Trial Close-Out Accrual
TipRanks · 09/24 00:27
Cynata Options Lapse, Streamlining ASX-Listed Capital Structure
TipRanks · 09/10 22:49
Cynata narrows loss but trial setbacks and cash squeeze deepen going-concern risk
TipRanks · 08/31 00:59
Cynata Plans ASX-Quoted Share Placement to Raise Capital
TipRanks · 08/25 08:08
Cynata Slashes Costs After Key Cell Therapy Trials Miss Efficacy Targets
TipRanks · 07/30 01:17
Cynata Options Lapse Clarifies Future Equity Structure
TipRanks · 07/09 22:57
Cynata Discloses Final Director Interest as Dr Darryl Maher Departs Board
TipRanks · 07/05 23:00
Cynata Slashes Costs, Axes Staff and Taps R&D Loan to Extend Cash Runway
TipRanks · 07/05 22:59
Major Shareholder FIL Limited Exits Position in Cynata Therapeutics
TipRanks · 07/02 08:47
Bioscience Fund Exits Substantial Holding in Cynata Therapeutics
TipRanks · 06/23 05:58
Cynata to Host Investor Webinar on Results Update
TipRanks · 06/21 23:07
Cynata’s CYP-004 Fails to Outperform Placebo in Phase 3 Knee Osteoarthritis Trial
TipRanks · 06/19 00:18
Cynata Halts CYP-001 GvHD Trial After Phase 2 Misses Efficacy Goals
TipRanks · 06/17 02:12
Cynata Seeks ASX Trading Suspension Ahead of Key Clinical Trial Results
TipRanks · 06/16 11:10
Cynata Sets June–July Timeline for Pivotal Stem Cell Trial Readouts
TipRanks · 05/26 23:15
Cynata Plans Placement of Up to 6 Million New Shares
TipRanks · 05/03 23:26
Cynata Nears Key Trial Readouts as Cell Therapy Sector Gains Traction
TipRanks · 04/30 01:46
More
Webull provides a variety of real-time CYYNF stock news. You can receive the latest news about Cynata Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About CYYNF
Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.